Relmada Therapeutics (RLMD) Expected to Announce Quarterly Earnings on Tuesday

Relmada Therapeutics (NASDAQ:RLMD) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter.

Relmada Therapeutics Trading Up 7.7 %

Shares of Relmada Therapeutics stock opened at $0.29 on Monday. The business’s 50 day simple moving average is $0.34 and its 200-day simple moving average is $1.75. The stock has a market capitalization of $8.83 million, a price-to-earnings ratio of -0.10 and a beta of 0.65. Relmada Therapeutics has a twelve month low of $0.24 and a twelve month high of $5.84.

Analyst Upgrades and Downgrades

Several research firms recently commented on RLMD. Leerink Partnrs cut Relmada Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 4th. Mizuho reaffirmed a “neutral” rating and set a $1.00 price target (down from $23.00) on shares of Relmada Therapeutics in a research note on Thursday, December 5th. Finally, Leerink Partners reissued a “market perform” rating and set a $1.00 price objective (down from $10.00) on shares of Relmada Therapeutics in a research note on Wednesday, December 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $4.25.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.